Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Meningococcal polysaccharide vaccine group W-135
- Development stage
- Approved
- Lead developer
- Sanofi Pasteur
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular, Subcutaneous
01
Overview
Meningococcal polysaccharide vaccine group W-135 is a biologic vaccine composed of purified capsular polysaccharides extracted from Neisseria meningitidis serogroup W‑135. It is used for active immunization to prevent invasive diseases such as meningitis and septicemia caused by this serogroup. The mechanism of action involves stimulating the immune system to produce antibodies against the bacterial capsule, thereby providing protection against infection. This component is often included in quadrivalent vaccines (covering groups A, C, Y, and W‑135) that are indicated for individuals at increased risk due to medical conditions or travel to endemic areas[1][5]. The primary developers and manufacturers have included Sanofi Pasteur and other major vaccine companies.
- Brand names
- MenquadfiMenveoNimenrixMenomune
- Other names
- Meningococcal polysaccharide antigen group W-135neisseria meningitidis group W-135 capsular polysaccharide antigenNeisseria meningitidis group W-135 polysaccharide antigen, A
02
Targets
MenW CPS (Neisseria meningitidis serogroup W capsular polysaccharide)
Beyond the preview
Go deeper on Meningococcal polysaccharide vaccine group W-135.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Meningococcal polysaccharide vaccine group W-135.